-
关于我们
Proji Company was founded in August 2004. It is a high-tech research and development enterprise established by returned overseas students, undertaking the task of industrializing and transforming various scientific research projects. -
Scientific research technology
Scientific research technology
科研技术
Proji Company is a constituent unit of the "National Engineering Research Center for Protein Technology" of Tsinghua University. It is the first national engineering laboratory established by the National Development and Reform Commission at Tsinghua University. Former President of the Chinese Academy of Sciences, Zhou Guangzhao, and the "Father of DNA", Nobel laureate James D. Watson served as honorary directors of the laboratory, with Professor Luo Yongzhang serving as the director. -
Products
公司产品
For nearly two decades, Proji Company has been primarily engaged in the development and production of recombinant protein drugs, antibody drugs, and in-vitro diagnostic reagents. It has established a unique R&D and large-scale preparation technology platform for recombinant protein drugs that has reached international standards. -
Project
项目公司
The company has long received strong support from various levels of government, including the National Development and Reform Commission, the Ministry of Science and Technology, and the municipal governments of Beijing, Yantai, Shenzhen, and Changzhou. -
新闻资讯
The company's marketing network spans 18 provinces and cities across the country (including 6 provinces and cities covered by medical insurance), benefiting more than 4 million patients, and gradually growing into a new benchmark in the biopharmaceutical industry. -
职业发展
From small-scale research institutions to advanced biopharmaceutical bases, the company's marketing network spans 18 provinces and cities across China.
Innovative R&D
Protgen is an important component unit of the National Engineering Research Center for Protgen Technology. In the nearly 20 years from the "Eleventh Five-Year Plan" to the "Thirteenth Five-Year Plan", it has undertaken or participated in 14 national-level projects and has rich experience in large-scale preparation of recombinant proteins, new drug research and development, and clinical trial research.
The company has a strong R&D team. Currently, 80% of the R&D personnel have master's degrees or above. It has independently developed a common key technology platform for large-scale preparation of recombinant protein drugs, and has rich practical experience in the research and development, management, and industrialization operation of recombinant protein drugs; the company maintains good communication and exchange with many domestic scientific research institutions, especially the close cooperation with Tsinghua University, has realized the integrated development of production, learning, and research. The company has mastered key common core technologies in the field of large-scale protein preparation, and has core competitiveness both at home and abroad; at the same time, it can also ensure the company's own low cost, high profitability, and form a continuous technological barrier.
Establish a platform for large-scale preparation of recombinant protein drugs, give full play to technical advantages, and have been successfully verified in the large-scale preparation of more than 250 proteins, such as:
(1) In a short period of time, a large-scale preparation process for polyethylene glycol recombinant human vascular endothelial inhibitor was established, supporting the upcoming completion of Phase II clinical trials of the national Class I candidate drug, polyethylene glycol recombinant human vascular endothelial inhibitor injection. Two other Class I candidate drugs have completed preclinical animal experiments, accumulating rich management experience in preclinical animal experiments, clinical trial design, and application.
(2) Developed the world's first clinically used quantitative detection kit for heat shock protein 90α (Hsp90α), obtained the national Class III (highest class) medical device certificate, and passed ISO13485 quality system certification and EU CE certification. The product has been approved to enter the Chinese and European markets. In 2013, the State Key Laboratory of Anti-tumor Protein Drugs proved for the first time in the world that Hsp90α is a novel tumor marker. As a component unit of the State Key Laboratory, Pro-G used its own technological advantages to quickly complete the large-scale preparation of Hsp90α protein and antibodies, and independently developed the Hsp90α quantitative detection kit, enabling this novel tumor marker to be used clinically.
(3) Research and development of recombinant human insulin series products. In 2013, participated in the "Major New Drug Creation" project "Key technology research and development of recombinant human insulin preparation" (project number: 2013ZX09509103). This project mainly researches recombinant human insulin, protamine zinc insulin, and related premixed products. Pro-G systematically optimized the preparation process of recombinant human insulin and other related products, overcame a series of key technical difficulties such as high-efficiency expression, high-density fermentation, high-concentration renaturation, high-efficiency enzymatic digestion, and high-efficiency purification, and established a high-efficiency preparation technology platform for insulin products, and a scalable preparation process that can be linearly scaled up to an annual output of tons of insulin. This process has low cost, high preparation efficiency, and simple operation.
(4) Research and development of ultra-high purity recombinant human serum albumin. Pro-G's recombinant human serum albumin project was launched only 9 months ago, and its key technical parameters are significantly leading.
Beijing Protgen Biotechnology Development Co., Ltd.
Tel:86010- 6297 9258
Postcode: 100085
Email:protgen@protgen.com
Address: No. 32, Chuangye Zhonglu, Haidian District, Beijing
Official Account QR Code
Maintenance Department QR Code
copyright © 2024 Beijing Progen Biotechnology Development Co., Ltd. Powered by：CEglobal TagsFriendly Links:Tsinghua UniversityNEC